Lupin to focus on development of inhalers with near-zero global warming potential propellants

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-11-03 05:30 GMT   |   Update On 2024-11-03 05:30 GMT

Mumbai: Global pharma major Lupin Limited has announced its focus on formulating respiratory inhalers by incorporating a propellant with near-zero global warming potential (GWP).

This initiative aims to provide patients with pressurised metered dose inhalers (pMDIs) that maintain the same efficacy and safety, while significantly reducing their environmental impact. This is aligned to the regulations in Europe and Lupin’s commitment to reducing its carbon footprint, the release stated.

Richard Dekhuijzen, em, professor of pulmonology at the Radboud university medical center in Nijmegen, the Netherland said, “The development of inhalers with near-zero global warming potential serves two major objectives: firstly, a maximal reduction of their environmental impact, and secondly, as important, keeping these medications available for those patients who really need these type of inhalers since they are unable to use dry powder inhalers.”

Vinita Gupta, Chief Executive Officer, Lupin said, “We are committed to making a positive impact in the lives of asthma patients worldwide. Our focus is on patient-centric sustainable healthcare innovation, ensuring that those who receive our pMDIs have reliable access to effective treatments with minimal impact to the environment.”

"In the respiratory category, our strategy includes the inhalation portfolio with accelerated development of pipeline products and green propellant development programs for early success.

We are committed to addressing environmental challenges impacting our patients and communities and actively pursue relevant initiatives for our respiratory solutions. We are working towards replacing standard propellants with near-zero (GWP) in our inhaler products, which will be fundamental to further establishing our position as a responsible pharmaceutical company," the Company stated.

Read also: Lupin names Claus Jepsen as President, Global Specialty

Lupin Limited is a global pharmaceutical Company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News